ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Small-Cell Lung Cancer in Milano, Lombardia

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Lung Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Colorectal Cancer
Triple Negative Breast Cancer

Non-Small-Cell Lung Cancer trials near Milano, Lombardia, ITA:

Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (DESTINY-LUNG02)

This study was designed to evaluate the safety and efficacy of trastuzumab deruxtecan in HER2-mutated metastatic non-small cell...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Trastuzumab deruxtecan

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Milano, Italy and 49 other locations

Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)

This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: DS-1062a

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Milano, Italy and 83 other locations

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with o...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Docetaxel
Drug: DS-1062a

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Milan, Italy and 209 other locations

Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)

type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and preliminarily assess its anti-cancer...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Sunvozertinib

Phase 1, Phase 2

Dizal Pharma

Milano, Italy and 123 other locations

A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell...

Active, not recruiting
Non Small Cell Lung Cancer
Biological: Telisotuzumab Vedotin

Phase 2

AbbVie
AbbVie

Monza, Monza E Brianza, Italy and 29 other locations

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

over time. The third main question is to see if ELVN-002 works to shrink cancers that have HER2 genetic abnormalities, particularly non...

Enrolling
HER2 Mutant Non-small Cell Lung Cancer
HER2-positive Metastatic Breast Cancer
Drug: ELVN-002
Drug: Trastuzumab emtansine

Phase 1

Enliven Therapeutics

Rozzano, Italy and 38 other locations

A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

PDCT in participants with previously untreated Stage IV or recurrent non-small cell lung cancer (NSCLC)....

Active, not recruiting
Metastatic Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Drug: Nab-Paclitaxel
Drug: Cisplatin

Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Milano, Italy and 126 other locations

A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ATLANTIC)

A study to assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: MEDI4736

Phase 2

AstraZeneca
AstraZeneca

Milano, Italy and 137 other locations

Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

NSCLC comprises of approximately 84 percent (%) of all lung cancers and is often diagnosed at advanced stage due to poor prognosis....

Active, not recruiting
Lung Cancer, Non-Small Cell
Drug: Pembrolizumab
Drug: Chemotherapy

Phase 2

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Milano, Lombardia, Italy and 57 other locations

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...

Active, not recruiting
Non-Small Cell Lung Cancer Metastatic
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Drug: Patritumab Deruxtecan (Fixed dose)
Drug: Patritumab Deruxtecan (Up-Titration)

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Milano, Italy and 123 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems